More papers !

diff --git a/open-source-biologist.mdwn b/open-source-biologist.mdwn
index 41a4ad954695c8d97ecbd4be9167bb71a7d96a2c..a7cabb822fb7b15c295bd579d8ba54e478648cb5 100644 (file)
--- a/open-source-biologist.mdwn
+++ b/open-source-biologist.mdwn
@@ -6,9 +6,9 @@ and zebrafish**, where I studied the activity of transcription enhancers
 ([Blader and coll., 2003](https://pubmed.gov/12559493)) and their evolutionary
 conservation ([Plessy and coll., 2005](https://pubmed.gov/15797614)). This gave
 me a strong interest for whole-transcriptome analysis and technology. For that
-purpose, I have joined RIKEN in 2004, where have worked on high-throughput
-methods for **profiling promoters and inferring gene networks**, and in
-particular on CAGE (Cap Analysis Gene Expression).
+purpose, I have worked at RIKEN in 2004–18  on high-throughput methods for
+**profiling promoters and inferring gene networks**, and in particular on CAGE
+(Cap Analysis Gene Expression).
 
 I have developed a miniaturized version of CAGE, termed **nanoCAGE**, to
 analyse small samples yielding only nanograms of RNA ([Plessy and coll.,
@@ -21,13 +21,15 @@ the molecular barcodes ([Tang and coll., 2013](https://pubmed.gov/23180801)),
 combining multiple cap-enrichment steps ([Batut and coll.,
 2013](https://pubmed.gov/22936248)), benchmarking the use of locked nucleic
 acids for template switching ([Harbers and coll.,
-2013](https://pubmed.gov/24079827)), and reducing the number of primer
-artefacts and unwanted sequences generated by ribosomal RNAs using
-low-complexity “pseudo-random” reverse-transcription primers ([Arnaud and
-coll., 2016](https://pubmed.gov/27071605)).
+2013](https://pubmed.gov/24079827)), reducing the number of primer artefacts
+and unwanted sequences generated by ribosomal RNAs using low-complexity
+“pseudo-random” reverse-transcription primers ([Arnaud and coll.,
+2016](https://pubmed.gov/27071605)), and screening for optimal parameters of
+the template-switching reaction ([Poulain and coll.,
+2020](https://pubmed.gov/32025730)).
 
-On April 2013, I started a new development cycle as the leader of the Genomics
-Miniaturization Technology Unit at RIKEN Center for Life Sciences, Division of
+In 2013–8, I lead a new development cycle at the Genomics
+Miniaturization Technology Unit in RIKEN's Center for Life Sciences, Division of
 Genomics Technology, to expand this work on single cells following a
 **population transcriptomics** approach ([Plessy and coll.,
 2013](https://pubmed.gov/23281054)) focused on sampling the largest possible
@@ -61,8 +63,10 @@ demonstrate the expression of haemoglobin in the midbrain ([Biagioli and coll.,
 localisation of RNA in **Purkinje neurons** ([Kratz and coll.,
 2014](https://pubmed.gov/24904046)), and neurogenesis in the mouse olfactory
 epithelium using single-cell CAGE and ATAC-seq techniques. In parallel with
-this promoter-centric work, I have also explored the huge repertoire of the **T
-cell antigen receptors**.
+this promoter-centric work, I have also explored the huge repertoire of the T
+cell antigen receptors.  I also applied the nanoCAGE technology to patient
+samples infected with the human papillomavirus (HPV) ([Taguchi and coll.,
+2020](https://pubmed.gov/33093512)).
 
 I joined OIST in 2018, to study **the genetic structure and population
 variations** of an animal plankton, _Oikopleura dioica_, that has a genome